[go: up one dir, main page]

PE20120877A1 - ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS - Google Patents

ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS

Info

Publication number
PE20120877A1
PE20120877A1 PE2011001751A PE2011001751A PE20120877A1 PE 20120877 A1 PE20120877 A1 PE 20120877A1 PE 2011001751 A PE2011001751 A PE 2011001751A PE 2011001751 A PE2011001751 A PE 2011001751A PE 20120877 A1 PE20120877 A1 PE 20120877A1
Authority
PE
Peru
Prior art keywords
hvr
sequence
seq
immunoconjugates
variant
Prior art date
Application number
PE2011001751A
Other languages
English (en)
Inventor
Kristi Elkins
Andrew Polson
Allen Ebens
Camelia Adams
Bing Zheng
Jagath R Junutula
Jo-Anne S Hongo
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120877(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20120877A1 publication Critical patent/PE20120877A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UN ANTICUERPO ANTI-FcRH5 QUE COMPRENDE: a) UNA SECUENCIA DE HVR SELECCIONADA DEL GRUPO: i) HVR-L1 DE SECUENCIA KASQNVGSNVA (SEQ ID NO:28), ii) HVR-L2 DE SECUENCIA SASYRYS (SEQ ID NO:29), iii) HVR-L3 DE SECUENCIA QQYKTWT (SEQ ID NO:30), iv) HVR-H1 DE SECUENCIA GYTFTNYGMN (SEQ ID NO:37), v) HVR-H2 DE SECUENCIA NTYTGEPTYTDDFKG (SEQ ID NO:38), vi) HVR-H3 DE SECUENCIA ARRSIPYYYAMDY (SEQ ID NO:39) Y b) UNA VARIANTE DE HVR, DONDE LA VARIANTE DE HVR COMPRENDE LA MODIFICACION DE UN RESIDUO DE LA SECUENCIA SEQ ID NO:28, 29, 30, 37, 38 O 39. TAMBIEN ESTA REFERIDA A UNA FORMULACION FARMACEUTICA Y A UN COMPUESTO CONJUGADO
PE2011001751A 2009-04-01 2010-03-31 ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS PE20120877A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21175409P 2009-04-01 2009-04-01
US16621409P 2009-04-02 2009-04-02

Publications (1)

Publication Number Publication Date
PE20120877A1 true PE20120877A1 (es) 2012-08-06

Family

ID=42236394

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001751A PE20120877A1 (es) 2009-04-01 2010-03-31 ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS

Country Status (18)

Country Link
US (2) US8362213B2 (es)
EP (1) EP2414395A1 (es)
JP (2) JP6099976B2 (es)
KR (1) KR20120003478A (es)
CN (1) CN102369218B (es)
AR (1) AR076030A1 (es)
AU (1) AU2010232682A1 (es)
BR (1) BRPI1012560A2 (es)
CA (1) CA2756988A1 (es)
CL (1) CL2011002418A1 (es)
IL (1) IL215404A0 (es)
MX (1) MX2011010265A (es)
PE (1) PE20120877A1 (es)
RU (2) RU2583270C2 (es)
SG (1) SG174930A1 (es)
TW (1) TW201039846A (es)
WO (1) WO2010114940A1 (es)
ZA (1) ZA201107128B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
MX2011010265A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
MX359217B (es) 2011-05-27 2018-09-19 Ambrx Inc Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN103747804B (zh) 2011-06-10 2016-08-17 梅尔莎纳医疗公司 蛋白质-聚合物-药物共轭物
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
PL2953976T3 (pl) * 2013-02-08 2021-11-02 Novartis Ag Specyficzne miejsca modyfikowania przeciwciał dla wytwarzania immunokoniugatów
JP5885885B2 (ja) 2013-03-29 2016-03-16 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
EP3015116B1 (en) 2013-06-24 2020-02-26 ABLBio Antibody-drug conjugate having improved stability and use thereof
AR096687A1 (es) * 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
IL245009B (en) 2013-10-11 2022-08-01 Asana Biosciences Llc Protein-polymer-drug conjugates
MX367851B (es) 2013-10-11 2019-09-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco.
PE20210648A1 (es) 2013-12-17 2021-03-26 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
MX2017003022A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados.
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
SG10202008076RA (en) 2014-12-05 2020-09-29 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
WO2016205176A1 (en) * 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック， インコーポレイテッド 抗ｃｌｌ－１抗体及び使用方法
HRP20231134T1 (hr) 2015-06-16 2024-01-05 F. Hoffmann - La Roche Ag Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
KR20180089497A (ko) * 2015-12-04 2018-08-08 메모리얼 슬로안-케터링 캔서 센터 Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법
WO2017188346A1 (ja) * 2016-04-27 2017-11-02 国立大学法人 東京大学 マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法
EP3471772A4 (en) * 2016-06-17 2020-03-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
AU2018289581C1 (en) * 2017-06-23 2025-01-30 VelosBio Inc. ROR1 antibody immunoconjugates
EP3658183A1 (en) 2017-07-28 2020-06-03 H. Hoffnabb-La Roche Ag Bispecific antibody formulation
PL3666787T3 (pl) * 2017-08-10 2024-04-29 Sumitomo Pharma Co., Ltd. Koniugaty przeciwciało-lek zawierające pochodną hemiasterliny
EP4321523A3 (en) * 2017-08-10 2024-04-24 Sumitomo Pharma Co., Ltd. Hemiasterlin derivatives and antibody-drug conjugates including same
US10766613B2 (en) * 2017-11-28 2020-09-08 Textron Innovations Inc. System and method for rotorcraft-weight-on-wheels flight state transition control
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US12180301B2 (en) 2018-03-06 2024-12-31 Imcare Biotech, Llc Serine protease inhibitor kazal (SPIK) compositions and methods
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020023106A1 (en) * 2018-07-25 2020-01-30 Northeastern University Selectivity screening for antimicrobial compounds
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7560255B2 (ja) * 2019-02-13 2024-10-02 住友ファーマ株式会社 ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
CA3127312A1 (en) 2019-02-13 2020-08-20 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin derivative having cysteine residue
US12178879B2 (en) 2019-02-13 2024-12-31 Sumitomo Pharma Co., Ltd. Hemiasterlin derivative and antibody-drug conjugate thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
EP3996816A1 (en) * 2019-07-08 2022-05-18 Imcare Biotech, LLC Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
EP4028132A1 (en) 2019-09-11 2022-07-20 Imcare Biotech, LLC Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
KR20220113790A (ko) 2019-12-13 2022-08-16 제넨테크, 인크. 항-ly6g6d 항체 및 사용 방법
BR112022011824A2 (pt) 2019-12-18 2022-08-30 Teneofour Inc Anticorpos de cadeia pesada que se ligam a cd38
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
IL298262A (en) 2020-06-23 2023-01-01 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
AU2021374592A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
JP2024515793A (ja) 2021-04-27 2024-04-10 ノバルティス アーゲー ウイルスベクター生産システム
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
IL308417A (en) 2021-05-14 2024-01-01 Genentech Inc Methods for the treatment of CD20-positive proliferative disorder with musuntozumab and folatuzumab and dotin
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
WO2023201299A1 (en) * 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of therapeutic proteins and methods of use
JP7579481B2 (ja) 2022-04-13 2024-11-07 ジェネンテック， インコーポレイテッド モスネツズマブの医薬組成物および使用方法
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN120112650A (zh) 2022-10-26 2025-06-06 诺华股份有限公司 慢病毒配制品
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024102948A1 (en) * 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
CA2173150C (en) 1993-10-01 2004-11-30 Kyoichi Sakakibara Novel peptide derivatives
US20030059780A1 (en) 1997-06-16 2003-03-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
JP2003532378A (ja) 1999-11-29 2003-11-05 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク リンパ腫／黒色腫の発症に関与する新規Ｆｃ受容体型黒色腫をコードする５つの新規遺伝子の単離
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
US7888478B2 (en) 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
JP2005511627A (ja) 2001-11-20 2005-04-28 シアトル ジェネティクス，インコーポレーテッド 抗ｃｄ３０抗体を使用する免疫学的疾患の治療
EP1575514A2 (en) 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
EP1696963A2 (en) 2003-12-24 2006-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP1753463A2 (en) * 2004-06-01 2007-02-21 Genentech, Inc. Antibody drug conjugates and methods
US7521541B2 (en) * 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US7999077B2 (en) 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
CN101103042A (zh) * 2005-01-12 2008-01-09 米德列斯公司 Irta-2抗体及其用途
ES2373080T3 (es) * 2005-06-20 2012-01-31 Genentech, Inc. Anticuerpos que se unen al antígeno tat10772 asociado a tumores para el diagnóstico y tratamiento de un tumor.
WO2008109533A2 (en) 2007-03-02 2008-09-12 Medarex, Inc. Human antibodies that bind multiple irta family proteins, and uses thereof
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
MX2011010265A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.

Also Published As

Publication number Publication date
US9017951B2 (en) 2015-04-28
RU2583270C2 (ru) 2016-05-10
ZA201107128B (en) 2012-12-27
US8362213B2 (en) 2013-01-29
MX2011010265A (es) 2011-10-11
WO2010114940A1 (en) 2010-10-07
TW201039846A (en) 2010-11-16
AR076030A1 (es) 2011-05-11
JP2016028052A (ja) 2016-02-25
KR20120003478A (ko) 2012-01-10
EP2414395A1 (en) 2012-02-08
JP6099976B2 (ja) 2017-03-29
US20110171125A1 (en) 2011-07-14
JP2012522513A (ja) 2012-09-27
SG174930A1 (en) 2011-11-28
AU2010232682A1 (en) 2011-11-10
CN102369218B (zh) 2014-07-16
CN102369218A (zh) 2012-03-07
HK1166805A1 (en) 2012-11-09
CL2011002418A1 (es) 2012-03-16
BRPI1012560A2 (pt) 2016-07-26
US20130089497A1 (en) 2013-04-11
IL215404A0 (en) 2011-12-29
CA2756988A1 (en) 2010-10-07
RU2016110891A (ru) 2018-11-27

Similar Documents

Publication Publication Date Title
PE20120877A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PE20120878A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
NZ597251A (en) Antibodies and immunoconjugates and uses therefor
PE20141114A1 (es) Anticuerpos anti-mesotelina e inmunoconjugados
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
PE20090943A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
ES2628108T3 (es) Anticuerpos multiespecíficos
PE20170935A1 (es) Anticuerpos anti-her2 e inmunoconjugados
PE20170670A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PE20141722A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20120553A1 (es) Anticuerpos anti-fgfr3
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
PE20150211A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
WO2013003680A8 (en) Anti-c-met antibody formulations
PE20121023A1 (es) Anticuerpos e inmunoconjugados
PE20140771A1 (es) Anticuerpos anti-ige apoptoticos
PE20201186A1 (es) Anticuerpos antitau y metodos de uso
PE20150614A1 (es) Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
AR091701A1 (es) Anticuerpos anti-cd22 e inmunoconjugados
CO6331344A2 (es) Anticuerpos aislados que unen a vegf, composiciones farmaceuticas que los comprenden y un portador farmaceuticamente aceptable y usos de los mismos
PE20161376A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso
PE20150945A1 (es) Anticuerpos de antihemaglutinina y metodos de uso

Legal Events

Date Code Title Description
FD Application declared void or lapsed